CA2943598C - S1p modulator immediate release dosage regimen - Google Patents

S1p modulator immediate release dosage regimen Download PDF

Info

Publication number
CA2943598C
CA2943598C CA2943598A CA2943598A CA2943598C CA 2943598 C CA2943598 C CA 2943598C CA 2943598 A CA2943598 A CA 2943598A CA 2943598 A CA2943598 A CA 2943598A CA 2943598 C CA2943598 C CA 2943598C
Authority
CA
Canada
Prior art keywords
siponimod
day
dosage form
treatment
immediate release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2943598A
Other languages
English (en)
French (fr)
Other versions
CA2943598A1 (en
Inventor
Eric Legangneux
Erik Wallstroem
Philippe Michael Rene BOUILLOT
Emeric Reynaud
Frank Dahlke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52988364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2943598(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA2943598A1 publication Critical patent/CA2943598A1/en
Application granted granted Critical
Publication of CA2943598C publication Critical patent/CA2943598C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2943598A 2014-04-10 2015-04-08 S1p modulator immediate release dosage regimen Active CA2943598C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461977816P 2014-04-10 2014-04-10
US61/977,816 2014-04-10
PCT/IB2015/052550 WO2015155709A1 (en) 2014-04-10 2015-04-08 S1p modulator immediate release dosage regimen

Publications (2)

Publication Number Publication Date
CA2943598A1 CA2943598A1 (en) 2015-10-15
CA2943598C true CA2943598C (en) 2023-03-07

Family

ID=52988364

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2943598A Active CA2943598C (en) 2014-04-10 2015-04-08 S1p modulator immediate release dosage regimen

Country Status (16)

Country Link
US (4) US20170027907A1 (en:Method)
EP (3) EP4074312A1 (en:Method)
JP (1) JP6674903B2 (en:Method)
KR (2) KR20160141841A (en:Method)
CN (2) CN116650467A (en:Method)
AU (2) AU2015246036A1 (en:Method)
CA (1) CA2943598C (en:Method)
CL (1) CL2016002562A1 (en:Method)
IL (2) IL305337A (en:Method)
MX (1) MX2016013245A (en:Method)
PH (1) PH12016501965A1 (en:Method)
RU (2) RU2020107732A (en:Method)
SG (1) SG11201607894RA (en:Method)
TW (1) TW201622721A (en:Method)
WO (1) WO2015155709A1 (en:Method)
ZA (1) ZA201606519B (en:Method)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (en:Method) 2014-01-24 2018-02-24
TW201622721A (zh) * 2014-04-10 2016-07-01 諾華公司 Ｓ１ｐ調節劑之立即釋放劑量療法
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US20200306222A1 (en) * 2017-09-29 2020-10-01 Novartis Ag Dosing Regimen of Siponimod
JP2020535147A (ja) * 2017-09-29 2020-12-03 ノバルティス アーゲー シポニモドの投与レジメン
FI3758708T3 (fi) 2018-03-01 2025-02-18 Astrazeneca Ab (2s)-{(1s)-1-syano-2-[4-(3-metyyli-2-okso-2,3-dihydro-1,3-bentsoksatsol-5-yyli)fenyyli]etyyli}-1,4-oksatsepaani-2-karboksamidia käsittäviä farmaseuttisia koostumuksia
KR20210032431A (ko) 2018-07-17 2021-03-24 인스메드 인코포레이티드 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
CN109908095A (zh) * 2019-04-08 2019-06-21 肇庆学院 一种西尼莫德片剂及制备方法
CA3156298A1 (en) 2019-10-31 2021-05-06 Laetitia POUZOL Combination of a cxcr7 antagonist with an s1p1 receptor modulator
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator
JP2026503035A (ja) 2023-01-06 2026-01-27 インスメッド インコーポレイテッド 新規な可逆性ｄｐｐ１阻害剤及びその用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2676953B1 (en) * 2008-12-18 2017-03-22 Novartis AG Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3 -trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid for use in the treatment of lymphocyte mediated diseases
JP5657565B2 (ja) * 2008-12-22 2015-01-21 ノバルティス アーゲー Ｓ１ｐ受容体アゴニストの投与レジメン
RS59857B1 (sr) * 2008-12-22 2020-02-28 Novartis Ag Režim doziranja agonista s1p receptora
RU2012117563A (ru) * 2009-09-29 2013-11-10 Новартис Аг Режим дозирования модулятора рецептора s1p
SG191286A1 (en) * 2011-01-07 2013-07-31 Novartis Ag Immunosuppressant formulations
WO2012095853A1 (en) * 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
EP2768494A1 (en) * 2011-10-21 2014-08-27 Novartis AG Dosage regimen for an s1p receptor modulator or agonist
TW201622721A (zh) * 2014-04-10 2016-07-01 諾華公司 Ｓ１ｐ調節劑之立即釋放劑量療法

Also Published As

Publication number Publication date
ZA201606519B (en) 2017-11-29
IL305337A (en) 2023-10-01
EP3831378A1 (en) 2021-06-09
RU2715734C2 (ru) 2020-03-03
PH12016501965A1 (en) 2017-01-09
EP4074312A1 (en) 2022-10-19
AU2020203107A1 (en) 2020-05-28
KR20220156981A (ko) 2022-11-28
RU2016143979A (ru) 2018-05-14
SG11201607894RA (en) 2016-10-28
TW201622721A (zh) 2016-07-01
RU2016143979A3 (en:Method) 2018-11-12
EP3129020A1 (en) 2017-02-15
CA2943598A1 (en) 2015-10-15
US20170027907A1 (en) 2017-02-02
IL247986A0 (en) 2016-11-30
US20250041266A1 (en) 2025-02-06
KR20160141841A (ko) 2016-12-09
CN116650467A (zh) 2023-08-29
JP6674903B2 (ja) 2020-04-01
MX2016013245A (es) 2017-01-16
JP2017510607A (ja) 2017-04-13
RU2020107732A (ru) 2020-03-30
CN106456552A (zh) 2017-02-22
AU2015246036A1 (en) 2016-10-13
US20220016076A1 (en) 2022-01-20
US20190054065A1 (en) 2019-02-21
WO2015155709A1 (en) 2015-10-15
AU2020203107B2 (en) 2021-10-21
CL2016002562A1 (es) 2017-07-28

Similar Documents

Publication Publication Date Title
US20250041266A1 (en) S1p modulator immediate release dosage regimen
TWI632909B (zh) 治療阿滋海默症之方法以及其醫藥組成物
CN117137912A (zh) 选择性s1p1受体激动剂的给药方案
CN102802418A (zh) 用于治疗肌萎缩性侧索硬化的组合物和方法
CA2682015A1 (en) Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
US20230338367A1 (en) Treatment of prurigo nodularis
CN102143687A (zh) 4-氨基吡啶在改善具有脱髓鞘和其它神经系统状况的患者的神经-认知和/或神经-精神病学损伤中的用途
JP7539898B2 (ja) オピオイド鎮痛耐性を治療するためのｍＧｌｕＲ５アンタゴニストの使用
EP4243782B1 (en) Tablet for use in treating huntington's disease and method of making the same
JP2698865B2 (ja) 筋緊張性ジストロフィー症治療剤
US20200016150A1 (en) Treatment of the pruritic symptoms of liver disease
HK40053433A (en) Siponimod immediate release dosage regimen for treating autoimmune diseases
HK40081576A (en) Siponimod immediate release dosage regimen for treating autoimmune diseases
US20080119501A1 (en) Immediate release oxymorphone compositions and methods of using same
CN1738626A (zh) 含有桂利嗪和茶苯海明的抗眩晕的组合制剂
TW202527911A (zh) 用於治療猝睡症的化合物
CA2973540C (en) Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US20220151938A1 (en) Tablet for use in treating huntington's disease and method of making the same
HK40101454B (en) Tablet for use in treating huntington's disease and method of making the same
HK40101454A (en) Tablet for use in treating huntington's disease and method of making the same
CA2973540A1 (en) Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
OA16802A (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200324

EEER Examination request

Effective date: 20200324

EEER Examination request

Effective date: 20200324

EEER Examination request

Effective date: 20200324